Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Red~Oneon Jan 06, 2022 9:50pm
79 Views
Post# 34291511

RE:RE:Sad but true.

RE:RE:Sad but true.
AngelaL wrote: There is of course a vast literature on the nitric oxide pathway in sexual dysfunction. Viagra, for example, works by stabilizing cGMP which is induced by endogenous nitric oxide. For female sexual dysfunction there is also a growing scientific literature, since the erectile function of the clitoris and the lubrication of the vagina are mediated by endogenous nitric oxide stimulation of cGMP. I have not seen any published work for R-107 in female sexual dysfunction but there are a number of published studies that have looked at other exogenous organic nitrates (eg NTG) and have observed dramatic effects on mucosal blood flow, clitoral engorgement, and vaginal secretion. The female sexual dysfunction market is relatively young but is growing. It would not be surprising if R-107 is highly effective in this setting. Thanks for starting the discussion on this topic. It is important. 

Whew, thanks for sharing
<< Previous
Bullboard Posts
Next >>